🟢 MannKind is trading 6.5% up today with no clear catalyst identified

MannKind is trading at $4.16, up 6.54% on October 1, 2026, with no new company announcement identified.

• September 30 coverage called the Delaware ruling that Yutrepia infringed a United Therapeutics patent positive for MannKind’s Tyvaso DPI royalty prospects; Truist maintained a Buy rating and $6 target.
• The report did not directly tie the move to the ruling. MannKind rose 16.77% in the prior session; Nasdaq gained 0.57%, leaving no clear market-wide explanation.